Clinical Trial Update: A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability and pharmacokinetics study of R932348 eye drops in keratoconjunctivitis Sicca (dry eye disease) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• R932348 Eye Drops (R932348)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Keratoconjunctivitis Sicca | Phase 1 | Status: COMPLETED